Loading…
IBIO
iBio, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 451033708
$1.36-2.86%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $67.56M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.54
- ROE
- -62.09%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.31
- 52-week high
- $3.82
- 52-week low
- $0.77
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.7% over 5Y.
today you would have $2.25▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.19 | $1.93 | $2.45 | $1.37 | $8.80 | $275.00 | $525.00 | $125.00 | $375.00 | $900.00 | $2,000.00 | $2,800.00 | $3,450.00 | $1,700.00 | $3,100.00 | $4,150.00 | |
| P/S | 42.4x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GOSSGossamer Bio, Inc. | $10.99 | — | — | — | — | $67.22M |
| CSBRChampions Oncology Inc | $4.93 | — | 17.4x | — | -29.97% | $68.5M |
| EXOZExozymes Inc | $7.17 | — | 18.2x | — | -187.16% | $66.53M |
| MDXHMDxHealth SA | $0.72 |
About the company
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- 20
- San Diego, United States
Company description provided by Yahoo Finance.